The intussusception market is expected to reach USD 5,802.37 Million d the market is projected to grow at a CAGR of 4.20% during the forecast period 2022-2030
Intussusception Market Overview
The Intussusception Market is anticipated to reach USD 5,802.37 Million by 2030 at 4.20% CAGR during the forecast period 2022-2030. Intussusception, also known as intestinal obstruction, is a potentially fatal disorder caused by the folding of one portion of the intestine into another, resulting in a bowel blockage. The obstruction obstructs the excretion process. Intussusception is the most common problem in children between 2 months to 2 years. Adults, on the other hand, maybe impacted by intussusception. It usually happens at the junction of the small and large intestines. Tumors, inflammation, Meckel's diverticulum, duplication, appendix, hyperplasia of Peyer's patches, intestinal surgery, polyps, tumors, inflammation, and other factors can all contribute to it. It induces tissue death by blocking the blood supply to the intestine. Infection, internal bleeding, ripping, intestinal injury, and peritonitis can all result from tissue death.Acute stomach discomfort, vomiting, nausea, fatigue, blood or mucus in the feces, constipation, and other symptoms of intussusception are the most common. Age, sex, faulty intestinal development at birth, a family history, and others are all risk factors for intussusception. The intussusception market is being driven by advances in the surgery segment, such as least invasive laparoscopic surgery. Market fragmentation in the medication category, on the other hand, has put downward pressure on pricing margins. The market's expansion has also been hampered by the loss of patents and the rise of counterfeit medications.
Sources: Mayo Clinic, Healthline Media, MRFR Analysis
The intussusception market has been segmented on the basis of type, diagnosis, treatment, and end user.
Based on the type, the Intussusception Market has been segmented as Ileoileal, Ileocolic, Ileo-ileo-colic, and others.
Based on the diagnosis, the Intussusception Market has been segmented as barium enema, ultrasound, X-ray, computerized tomography (CT), and others.
Based on the surgery, the Intussusception Market has been segmented as surgery, drugs, and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
The Americas accounts for a significant market share owing to extensive volume of surgeries performed and high expenditure on the health care. Additionally, the fastest uptake of new products and surgical procedures in the US drives the intussusception market. Furthermore, concentration of the major healthcare companies in the developed countries of this region coupled with large insurance penetration is adding fuel to the market growth. Moreover, the US expend high on the healthcare, which accounts for 16% of total GDP also increase the sale of intussusception treatment.
Europe is the second largest market in the world due to high income and strong healthcare penetration. European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period.
Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as Vietnam, Thailand, and Malaysia are projected to contribute highly to the market growth.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions, and poor healthcare development.Recent Development
Baxter's decision in December 2019 to purchase the Seprafilm adhesion barrier and related assets from Sanofi, one of the market's leading players, complimented its hemostat and sealant portfolio and bolstered the company's foothold in the Intussusception Market.
The firms combined their resources and positioned themselves as leaders in the worldwide medical device technology industry, including the adhesion barriers market, after BD purchased C.R.Bard in December 2017. The Oxiplex/IU Intrauterine Adhesion Barrier gel was introduced by FzioMed in October 2018 in the Intussusception Market.
Key Players in the Intussusception Market
Some of the key players profiled in the report are Pfizer, Inc., Janssen Pharmaceuticals, Inc., Abbott, GlaxoSmithKline plc, sanofi-aventis U.S. LLC. , Novartis AG, Bayer AG, FUJIFILM Holdings Corporation, General Electric Company, Shimadzu Corporation, Carestream Health, Bristol-Myers Squibb Company, and others.
intussusception market can progress at 4.20% CAGR from 2022 to 2030.
intussusception market size can touch USD 5,802.37 Million by 2030.
Rising incidence of the intestinal disorder among infants is the major driver of the global intussusception market.
Concerns of surgery and its high costs is likely to deter the global intussusception market growth.
The Americas has the largest share of the global intussusception market due to large volume of surgeries.
A Carestream Health, Abbott, General Electric Company, Novartis AG, Bayer AG, Pfizer, Inc., Janssen Pharmaceuticals, Inc., FUJIFILM Holdings Corporation, Shimadzu Corporation, Sanofi-Aventis U.S. LLC, GlaxoSmithKline plc, and Bristol-Myers Squibb Company are major players of the global intussusception market.